Press Releases

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Forma disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date	Title	Additional Formats
Nov 12, 2020	Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update	PDF Version
Nov 10, 2020	Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease	PDF Version
Nov 04, 2020	Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at Upcoming 2020 ASH Virtual Annual Meeting	PDF Version
Nov 04, 2020	Forma Therapeutics to Participate in Upcoming Investor Conferences	PDF Version
Oct 26, 2020	Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)	PDF Version
Sep 15, 2020	Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions	PDF Version
Sep 09, 2020	Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors	PDF Version
Aug 13, 2020	Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update	PDF Version
Jul 30, 2020	Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors	PDF Version
Jun 23, 2020	Forma Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares	PDF Version

© 2020 ALL RIGHTS RESERVED

ADDRESS

500 Arsenal Street, Suite 100
Watertown, MA 02472
617.679.1970

SOCIAL MEDIA